share_log

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

Benzinga ·  Oct 23 07:11  · Ratings

EF Hutton analyst Jason Kolbert initiates coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment